The incoming chief executive at St. Jude Medical (NYSE:STJ) isn’t even in the corner office yet, but Michael Rousseau isn’t letting any grass grow under his feet.
Rousseau, who’s slated to succeed longtime CEO Daniel Starks next year, announced a slate of executive changes today, elevating 1 senior vice president to the executive committee and expanding the purviews of several others, effective Jan 1, 2016.
Little Canada, Minn.-based St. Jude said it promoted Phil Eberling from senior vice president of R&D for electrophysiology & cardiovascular to vice president and chief technology officer and gave him a seat on the company’s executive committee.
Group president Dr. Eric Fain is slated to add responsibility for global sales & marketing to his clinical oversight duties, with chief marketing officer Lisa Andrade; Americas sales president Joel Becker; global clinical affairs VP Dr. Mark Carlson; and international sales president Denis Gestin all reporting to Fain.
CFO Don Zurbay is due to take on the investor relations role and oversee CIO Mark Murphy. General counsel Jason Zellers was given responsibility for St. Jude’s quality organization, overseeing global quality VP Jeffry Fecho.
Global communications vice president Rachel Ellingson was named VP of corporate strategy, keeping her PR duties and adding business development and M&A integration to her duties; John Heinmiller will stay on as executive vice president to “focus his efforts in a senior advisory capacity to help ensure a seamless leadership transition,” a St. Jude spokeswoman told MassDevice.com via email today.
Paul Bae and Scott Thome are slated to keep their roles as vice president of HR & chief compliance officer and global operations VP, respectively.
“We are fortunate to have an executive team that’s uniquely qualified to continue St. Jude Medical’s growth story,” Rousseau said in prepared remarks. “This is a remarkable team with a diverse set of experiences and a proven track record that will allow us to continue to transform and diversify the way we develop medical technologies in order to improve the care for patients around the world. Over the past several years, our executive team has made significant contributions to the business and shares in the excitement of the future of St. Jude Medical.”
